Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
Atai Beckley N.V. (ATAI) furnished an update via Form 8-K, noting it issued a press release announcing financial results for the quarter ended September 30, 2025 and provided corporate and clinical updates. The press release is attached as Exhibit 99.1. The company stated the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless specifically noted.
Atai Beckley N.V. (ATAI) reported insider activity on November 5, 2025. A director received several stock option grants: three fully vested options at an exercise price of $1.35 covering 456,011, 97,716, and 62,394 common shares with expirations from July 2025 to October 2032, and an additional 103,000 options at $4.48 expiring in November 2035 that vest on the first anniversary of the grant date.
On the same date, the company completed its acquisition of Beckley Psytech Limited, issuing 103,000,066 common shares as consideration or as underlying replacement awards pursuant to the purchase agreement.
Atai Beckley N.V. (ATAI) reported an insider transaction: a director acquired 7,702,990 common shares on November 5, 2025. The filing notes this occurred in connection with the Issuer’s completion of its acquisition of Beckley Psytech, for which an aggregate of 103,000,066 common shares were issued as consideration or as underlying replacement awards.
The director also received two stock option grants with a $4.48 exercise price, covering 103,000 and 40,400 shares, each expiring on November 5, 2035. One option vests in full on the first anniversary of the grant date, and the other vests in 12 substantially equal monthly installments beginning December 5, 2025. Following the transactions, the director held 7,702,990 common shares directly.
Atai Beckley N.V. (ATAI) reported a director’s Form 4 reflecting a new stock option grant. On 11/04/2025, the director was granted 56,818 stock options with an exercise price of $5.28 per share. The option expires on 11/04/2035 and will vest as to 100% of the underlying shares on the first anniversary of the grant date.
Following the reported transaction, the director beneficially owned 56,818 derivative securities, held directly. The filing notes the transaction code “A,” indicating an option grant.
Atai Beckley N.V. (ATAI) reported an insider status update: a director filed a Form 3 for an event dated 11/05/2025.
The filing states no securities are beneficially owned. It was filed by one reporting person, with execution by an attorney-in-fact pursuant to Exhibit 24 (Power of Attorney).
Atai Beckley N.V. (ATAI) insider filing: A director filed an initial Form 3 reflecting their status as a board member as of 11/05/2025. The filing states that no securities are beneficially owned by the reporting person at this time. The form was submitted by attorney-in-fact Ryan Barrett under a Power of Attorney (Exhibit 24). This is an administrative disclosure establishing insider reporting status and current holdings.
Atai Beckley N.V. filed a prospectus supplement covering the resale from time to time by certain selling securityholders of up to 5,316,238 common shares. The registration satisfies rights granted in connection with the Company’s acquisition of the issued share capital of Beckley Psytech Limited not already owned by the Company.
The Company also filed a legal opinion from NautaDutilh N.V. as Exhibit 5.1 regarding the validity of the shares, along with a related consent and the cover page interactive data file.
ATAI Life Sciences filed a prospectus supplement to register for resale up to 5,316,238 common shares previously issued to selling securityholders in connection with the acquisition of Beckley Psytech. The shares may be sold from time to time by the holders using various methods described in the document.
ATAI will not receive proceeds from sales by the selling securityholders, though it will cover certain registration expenses. The shares trade on the Nasdaq Global Market under the symbol ATAI. As context, shares outstanding were 363,114,450 as of November 5, 2025.
The resale registration lists individual holder amounts, including Shlomi Raz 3,268,819 and Cantor Fitzgerald & Co. 900,901. Sales may occur through underwriters, dealers, agents, or direct transactions at market, related, fixed, or negotiated prices.
Atai Beckley N.V. (NASDAQ: ATAI) completed its previously announced acquisition of the issued share capital of Beckley Psytech Limited not already owned by the company. The transaction closed on November 5, 2025 and was executed under the June 2, 2025 Share Purchase Agreement, as amended.
As consideration, the company issued an aggregate of 103,000,066 ordinary shares, delivered directly as share consideration or as underlying replacement awards to Beckley Psytech shareholders, certain consultants, and equity award holders. In connection with closing, the company changed its name to Atai Beckley N.V.
The company furnished a press release announcing completion of the acquisition as Exhibit 99.1.
atai Life Sciences (ATAI) reported shareholder approvals tied to its proposed Beckley Psytech acquisition and corporate reorganization. Holders approved the Acquisition Proposal with 121,090,088 votes for, and authorized the related share issuance under Nasdaq Rule 5635(a) with 120,951,244 votes for. Shareholders also elected Cosmo Feilding-Mellen and Dr. Robert Hershberg as non-executive directors and approved governing document changes.
Steps toward redomiciliation advanced, including approval of a merger with atai Life Sciences Luxembourg S.A. and related charter amendments addressing withdrawal-right cash compensation and potential B share conversion. As of October 7, 2025, shares outstanding were 240,488,841; 156,318,136 shares were present or represented at the meeting. Completion of the redomiciliation remains subject to closing conditions.